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Treatment of individuals at higher risk of cardiovascular events with primary prevention medication 
has been an important part of coronary care for over 20 years. During this time, substantial gains 
have been made in reducing mortality from coronary heart disease (CHD),(1) in part due to use of 
primary prevention medications such as statins.(2) Yet, at all ages,  these gains in mortality reduction 
have not been shared equally between men and women.(3,4) While the causes of these age and sex 
differences in mortality reductions are not well understood, it is recognised that cardiovascular risk 
estimates by primary care physicians are often imprecise, contributing to suboptimal preventive 
treatment in real-world clinical practice.(5) There is a need for more accurate sex-specific risk 
assessment, based on better understanding of sex differences in the way circulating biomarkers 
affect cardiovascular outcomes, in order to drive further reductions in cardiovascular disease (CVD) 
mortality.  
Dr Gohar and colleagues have undertaken a substantial systematic review of the evidence for sex 
differences in baseline levels of established and emerging plasma-based biomarkers and their 
associations with cardiovascular outcomes.(6) Some biomarkers, such as Lp(A) and LDL-C,  have been 
the subject of multiple studies the results of which often contradict each other while other studies 
have shown greater consistency about the associations between  raised biomarker levels and 
associations with cardiovascular disease in men or women.   The importance of understanding the 
nuances of risk associated with differing levels of circulating biomarkers is demonstrated by lipid 
studies in which women consistently have higher concentrations of HDL cholesterol but the same 
association with CVD endpoints compared with men, while baseline levels of LDL cholesterol were 
similar for both sexes but the strength of association with CVD endpoints varied, one study favouring 
men and another favouring women.   
  
Evaluating the meaningfulness of these results is further complicated by studies included in the 
review a) being of variable quality, b) coming from different periods in recent cardiovascular history, 
c) including different age groups and examining different CVD outcomes. Gohar et al successfully 
identify the association of risk factors with specific CVD endpoints - they included a range of 
outcomes including coronary heart disease (CHD), heart failure, atrial fibrillation and stroke as well 
as composite outcomes – the authors do not provide any comparisons of how endpoints are 
measured or discuss how differences in outcome definitions might help in understanding conflicting 
findings. Nor have all outcomes been subject to the same sex-specific analysis and like a previous 
review  far more studies have focussed on sex differences in coronary heart disease than in 
stroke.(7) 
 
In what is perhaps a greater service to understanding in this area, Gohar et al. have also documented 
the paucity of studies that have presented sex-specific results. The authors identified 360 papers on 
the association between selected biomarkers and CVD outcomes in healthy populations.  Out of 
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these, 171 were single sex studies. A further 134 did not report sex-specific results, leaving a total of 
55 papers with direct comparisons between men and women.  The authors point out that both men 
and women were well represented in the studies included in the review, offering multiple 
opportunities for sex-specific analyses which were not taken. Particularly disappointing, as the 
authors point out, is that with emerging biomarkers there are no studies reporting sex-specific 
results, despite earlier animal studies indicating significant differences by sex. The lost opportunity 
from 85% of the studies in this area not providing relevant analyses to help understand the 
underlying aetiology of cardiovascular disease suggests the need for more organised action by the 
scientific community to ensure this happens in future.  
The United States has led the way with taking organised action to ensure better understanding of 
differences between men and women in the development of disease with the National Institutes for 
Health (NIH) Revitalisation Act in 1973 requiring inclusion of women in all NIH-funded clinical 
research, followed in 2014 by a requirement for gender balance in all cell and animal studies.(8) The 
European Commission has more recently joined the fray with an explicit requirement for gender 
equality in research, including  required  integration of “… the gender dimension in the content of 
Research and Innovation”.(9) The newly published Lancet Commission on Women and Health has 
called for research funding agencies to mandate that research studies enrol women and make sex 
differences a core component of research, and more specifically that “basic, clinical, social science 
and public health research projects disaggregate study populations by sex and explicitly consider 
gender in their design, implementation, analysis and reporting”.(10) 
One of the difficulties of such requirements is the need for larger sample sizes with sufficient power 
to allow disaggregated analyses. NIH is addressing this point by supporting existing grant holders 
with additional funding to recruit additional subjects. Electronic health records provide an 
alternative means of generating large cohorts for outcomes research but although well powered for 
comparative analyses by gender their application for studying emerging biomarkers is more 
limited.(11–13)   
So does investment in sex-specific analyses make a useful difference to the accuracy of risk 
prediction? Answers are difficult but it is instructive to reflect on the evolution of the American 
Heart Association’s guideline on the prevention of coronary heart disease in women. First published 
as a consensus panel statement in 1999 with limited references,(14) it has now evolved into an 
effectiveness-based guideline with six times as many references as sex-specific data on risk factors 
for coronary heart disease have accumulated.(15) With greater consistency in publishing sex-specific 
analyses, the evolution of our understanding of cardiovascular risk in men and women will continue 
to develop.  
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